Skip to main content
. Author manuscript; available in PMC: 2021 Mar 31.
Published in final edited form as: Nat Cancer. 2020 Oct 19;1(11):1113–1127. doi: 10.1038/s43018-020-00124-1

Extended Fig. 5 |. Schematics of the protein structures showing mutations recurrently identified in diagnostic and relapse ALL samples.

Extended Fig. 5 |

Proteins involved in epigenetic regulation and other recurrently mutated factors are represented. Black circles indicate amino acid substitutions. Red circles indicate truncating mutations. TAZ, TAZ zinc finger; KIX, kinase-inducible domain interacting domain; Bromo, bromodomain; HAT, histone acetyl transferase domain; PWWP, proline (P) tryptophan (W) tryptophan (W) proline (P) domain; HMG, high mobility group domain; PHD, plant homeodomain; SET, Su(var)3–9 Enhancer of zeste and Trithorax domain; AWS, associated with SET; SRI, Set2 Rpb1 interacting; MED12, Mediator complex, subunit Med12; FYRN, FY-rich domain N-terminal; UBL, ubiquitin like domain; USP, ubiquitin specific protease domain; ITD, ion transport domain; PH, pleckstrin homology; GED, GTPase effector domain; PRD, proline/arginine-rich domain; Neur_chan_LBD, Neurotransmitter-gated ion-channel ligand binding domain; LIC, Cation transporter family protein; Neur_chan_memb, Neurotransmitter-gated ion-channel transmembrane region; TRAF, tumor necrosis factor-receptor associated factor; HUBL, HAUSP/USP7 ubiquitin-like domain; FN3_D, Fibronectin type III-like domain; SEFIR, SEF/IL-17R; Myc_N, Myc amino-terminal region; HLH, Helix-loop-helix; LZ, leucine zipper; Jmjc, Jumonji C.